These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8203844)

  • 1. Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses.
    Bertino JS; Nafziger AN; Wong M; Stragand L; Puleo C
    Antimicrob Agents Chemother; 1994 Mar; 38(3):499-503. PubMed ID: 8203844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.
    Lubowski TJ; Nightingale CH; Sweeney K; Quintiliani R
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2758-60. PubMed ID: 1482143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
    Dan M; Weidekamm E; Sagiv R; Portmann R; Zakut H
    Antimicrob Agents Chemother; 1993 Feb; 37(2):293-6. PubMed ID: 8452360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
    Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
    Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
    Schrenzel J; Cerruti F; Herrmann M; Leemann T; Weidekamm E; Portmann R; Hirschel B; Lew DP
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1219-24. PubMed ID: 8092817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fleroxacin clinical pharmacokinetics.
    Stuck AE; Kim DK; Frey FJ
    Clin Pharmacokinet; 1992 Feb; 22(2):116-31. PubMed ID: 1551289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.
    Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD
    Biopharm Drug Dispos; 2000 Jan; 21(1):33-40. PubMed ID: 11038436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetration of fleroxacin into human and animal tissues.
    Portmann R; Weidekamm E
    Chemotherapy; 1992; 38(3):145-9. PubMed ID: 1511632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of fleroxacin in horses.
    Rebuelto M; Otero P; Albarellos G; Ambros L; Kreil V; Waxman S; Montoya L; Hallu R
    J Vet Pharmacol Ther; 2000 Apr; 23(2):103-5. PubMed ID: 10849255
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
    Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
    Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the pharmacokinetics of fleroxacin.
    Nightingale CH
    Am J Med; 1993 Mar; 94(3A):38S-43S. PubMed ID: 8452184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of food on the pharmacokinetics of sparfloxacin.
    Johnson RD; Dorr MB; Hunt TL; Jensen BK; Talbot GH
    Clin Ther; 1999 Jun; 21(6):982-91. PubMed ID: 10440622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.
    Wonnemann M; Schug B; Schmücker K; Brendel E; van Zwieten PA; Blume H
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):38-48. PubMed ID: 16425970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fleroxacin determined by biological method.
    Verbist L; Van Hecken A; De Schepper P
    J Chemother; 1989 Jul; 1(4 Suppl):572-3. PubMed ID: 16312537
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of rifampin on fleroxacin pharmacokinetics.
    Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.